Screening for Prostate Cancer
Abstract
This JAMA Patient Page discusses the US Preventive Services Task Force’s recommendations on screening for prostate cancer in asymptomatic men.
Abstract
R. Waidelich, H. Jansen, Petra Stieber, N. Schmeller, Rolf Lamerz, Karl Werdan, A. Fateh‐Moghadam (1997)
Screening for prostatic carcinoma with prostate specific antigen.Anticancer research, 17 4B
E. Vertosick, Bing Poon, A. Vickers (2014)
Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening.The Journal of urology, 192 3
E. Heijnsdijk, E. Wever, A. Auvinen, J. Hugosson, S. Ciatto, V. Nelen, M. Kwiatkowski, A. Villers, Á. Páez, S. Moss, M. Zappa, T. Tammela, T. Mäkinen, S. Carlsson, I. Korfage, M. Essink‐bot, S. Otto, G. Draisma, C. Bangma, M. Roobol, F. Schröder, H. Koning (2012)
Quality-of-life effects of prostate-specific antigen screening.The New England journal of medicine, 367 7
Frank-Jan Drost, D. Osses, D. Nieboer, C. Bangma, E. Steyerberg, M. Roobol, I. Schoots (2020)
Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.European urology
G. Draisma, Ruth Etzioni, A. Tsodikov, A. Mariotto, E. Wever, R. Gulati, E. Feuer, H. Koning (2009)
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.Journal of the National Cancer Institute, 101 6
Sigrid Carlsson, Sigrid Carlsson, J. Eastham, E. Crawford, R. Harris (2020)
"PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older.European urology
T. Li, C. Beling (1973)
Isolation and characterization of two specific antigens of human seminal plasma.Fertility and sterility, 24 2
H. Welch, Barnett Kramer, W. Black (2019)
Epidemiologic Signatures in Cancer.The New England journal of medicine, 381 14
E. Vertosick, Christel Häggström, D. Sjoberg, G. Hallmans, R. Johansson, A. Vickers, P. Stattin, H. Lilja (2020)
Prespecified Four Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population-Based Cohort of Asymptomatic Men Followed for 20 Years.Journal of Urology
J. Eastham, E. Riedel, P. Scardino, M. Shike, M. Fleisher, A. Schatzkin, E. Lanza, L. Latkany, C. Begg (2003)
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.JAMA, 289 20
T. Stamey, N. Yang, A. Hay, J. McNeal, F. Freiha, E. Redwine (1988)
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.The New England journal of medicine, 317 15
(2019)
Epidemiologic Signatures in Cancer. The New England journal of medicine
A. Vickers, C. Savage, M. Hruza, I. Tuerk, P. Koenig, L. Martínez-Piñeiro, G. Janetschek, B. Guillonneau (2009)
The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study.The Lancet. Oncology, 10 5
(2015)
Metastatic Prostate Cancer Incidence and Prostatespecific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer
(1913)
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Jama
W. Cooner, B. Mosley, Charles Rutherford, J. Beard, H. Pond, W. Terry, T. Igel, D. Kidd (1990)
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen.The Journal of urology, 143 6
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
S. Loeb, N. Byrne, Binhuan Wang, D. Makarov, D. Becker, D. Wise, H. Lepor, D. Walter (2020)
Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System.European urology
A. Vickers, S. Carlsson, V. Laudone, H. Lilja (2014)
It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening.European urology, 66 2
A. Vickers, A. Cronin, T. Björk, J. Manjer, P. Nilsson, A. Dahlin, A. Bjartell, P. Scardino, D. Ulmert, H. Lilja (2010)
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control studyThe BMJ, 341
S. Loeb, M. Bjurlin, Joseph Nicholson, T. Tammela, D. Penson, H., Ballentine Carter, Peter Carroll, R. Etzioni (2014)
Overdiagnosis and overtreatment of prostate cancer.European urology, 65 6
A. Vickers, J. Eastham, P. Scardino, H. Lilja (2016)
The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.Urology, 91
(2011)
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. The Lancet Oncology
K. Hoffman, D. Penson, Zhiguo Zhao, Li-Ching Huang, R. Conwill, A. Laviana, Daniel Joyce, A. Luckenbaugh, M. Goodman, A. Hamilton, Xiao-Cheng Wu, L. Paddock, A. Stroup, M. Cooperberg, M. Hashibe, Brock O'Neil, S. Kaplan, S. Greenfield, T. Koyama, D. Barocas (2020)
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.JAMA, 323 2
L. Klotz (2015)
Active Surveillance for Low-Risk Prostate CancerCurrent Urology Reports, 16
N. Pashayan, S. Duffy, D. Neal, F. Hamdy, J. Donovan, Richard Martin, P. Harrington, S. Benlloch, A. Olama, M. Shah, Z. Kote-Jarai, D. Easton, R. Eeles, P. Pharoah (2014)
Abstract 261: Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosisCancer Research, 74
A. Vickers, K. Edwards, M. Cooperberg, A. Mushlin (2014)
A Simple Schema for Informed Decision Making About Prostate Cancer ScreeningAnnals of Internal Medicine, 161
S. Loeb, A. Vellekoop, H. Ahmed, J. Catto, M. Emberton, R. Nam, D. Rosario, V. Scattoni, Y. Lotan
Platinum Priority – Review – Prostate Cancer Systematic Review of Complications of Prostate Biopsy
Megan McIntosh, M. Opozda, Holly Evans, Amy Finlay, D. Galvão, S. Chambers, C. Short (2019)
A systematic review of the unmet supportive care needs of men on active surveillance for prostate cancerPsycho‐Oncology, 28
Jonathan Shoag, S. Mittal, Jim Hu (2016)
Reevaluating PSA Testing Rates in the PLCO Trial.The New England journal of medicine, 374 18
P. Pinsky, Eric Miller, P. Prorok, R. Grubb, E. Crawford, G. Andriole (2018)
Extended follow‐up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trialBJU International, 123
F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Luján, H. Lilja, M. Zappa, L. Denis, F. Recker, Á. Páez, L. Määttänen, C. Bangma, G. Aus, S. Carlsson, A. Villers, X. Rébillard, T. Kwast, P. Kujala, B. Blijenberg, U. Stenman, A. Huber, K. Taari, M. Hakama, S. Moss, H. Koning, A. Auvinen (2012)
Prostate-cancer mortality at 11 years of follow-up.The New England journal of medicine, 366 11
P. Pinsky, A. Black, B. Kramer, A. Miller, P. Prorok, C. Berg (2010)
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialClinical Trials, 7
K. Kohestani, M. Chilov, S. Carlsson (2018)
Prostate cancer screening—when to start and how to screen?Translational Andrology and Urology, 7
M. Cooperberg, P. Carroll (2015)
Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.JAMA, 314 1
P. Agostinis, K. Berg, K. Cengel, T. Foster, A. Girotti, S. Gollnick, S. Hahn, Michael Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mróz, D. Nowis, J. Piette, B. Wilson, J. Gołąb (2011)
CA : A Cancer Journal for Clinicians
H. Carter, P. Albertsen, M. Barry, Ruth Etzioni, S. Freedland, Kirsten Greene, L. Holmberg, P. Kantoff, B. Konety, M. Murad, D. Penson, A. Zietman (2013)
Early detection of prostate cancer: AUA Guideline.The Journal of urology, 190 2
E. Kovac, S. Carlsson, H. Lilja, J. Hugosson, M. Kattan, E. Holmberg, A. Stephenson (2020)
Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 YearsJAMA Network Open, 3
M. Preston, T. Gerke, S. Carlsson, L. Signorello, D. Sjoberg, S. Markt, A. Kibel, Q. Trinh, M. Steinwandel, W. Blot, A. Vickers, H. Lilja, L. Mucci, K. Wilson (2019)
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.European urology, 75 3
A. Vickers, F. Bianco, A. Serio, J. Eastham, D. Schrag, E. Klein, Alwyn Reuther, M. Kattan, J. Pontes, P. Scardino (2007)
The surgical learning curve for prostate cancer control after radical prostatectomy.Journal of the National Cancer Institute, 99 15
M. Aly, F. Wiklund, Jianfeng Xu, W. Isaacs, M. Eklund, M. D’Amato, J. Adolfsson, H. Grönberg (2011)
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.European urology, 60 1
C. Savage, A. Vickers (2009)
Low annual caseloads of United States surgeons conducting radical prostatectomy.The Journal of urology, 182 6
Sam Chen, Jean Fann, C. Sipeky, Teng-Kai Yang, S. Chiu, A. Yen, Virpi Laitinen, T. Tammela, U. Stenman, A. Auvinen, J. Schleutker, Hsiu-Hsi Chen (2019)
Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific AntigenThe Journal of Urology, 201
Bo Feng, M. Srinivasan, J. Hoffman, Julie Rainwater, E. Griffin, Marko Dragojevic, Frank Day, M. Wilkes (2013)
Physician Communication Regarding Prostate Cancer Screening: Analysis of Unannounced Standardized Patient VisitsThe Annals of Family Medicine, 11
A. Herlemann, C. Stief (2016)
[Active surveillance for low-risk prostate cancer].Der Urologe. Ausg. A, 55 2
J. Eastham (2009)
Do high-volume hospitals and surgeons provide better care in urologic oncology?Urologic oncology, 27 4
W. Mc, L. Valenzuela, G. Murphy, T. Chu (1979)
Purification of a human prostate specific antigen.Investigative urology, 17 2
(1971)
Some physico-chemical characteristics of “ seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion
Scott Kelly, W. Anderson, P. Rosenberg, M. Cook (2017)
Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.European urology focus, 4 1
F. Schumacher, A. Olama, S. Berndt, S. Benlloch, Mahbubl Ahmed, E. Saunders, Tokhir Dadaev, D. Leongamornlert, Ezequiel Anokian, C. Cieza-Borrella, C. Goh, M. Brook, Xin Sheng, L. Fachal, J. Dennis, J. Tyrer, K. Muir, A. Lophatananon, V. Stevens, S. Gapstur, B. Carter, C. Tangen, P. Goodman, I. Thompson, J. Batra, S. Chambers, Leire Moya, J. Clements, L. Horvath, W. Tilley, G. Risbridger, H. Gronberg, M. Aly, T. Nordström, P. Pharoah, N. Pashayan, J. Schleutker, T. Tammela, C. Sipeky, A. Auvinen, D. Albanes, S. Weinstein, A. Wolk, N. Håkansson, C. West, A. Dunning, N. Burnet, L. Mucci, E. Giovannucci, G. Andriole, O. Cussenot, G. Cancel-Tassin, Stella Koutros, L. Freeman, K. Sørensen, T. Orntoft, M. Borre, L. Maehle, E. Grindedal, D. Neal, J. Donovan, F. Hamdy, Richard Martin, R. Travis, T. Key, R. Hamilton, N. Fleshner, A. Finelli, S. Ingles, M. Stern, B. Rosenstein, S. Kerns, H. Ostrer, Yong-jie Lu, Hong-wei Zhang, Ninghan Feng, Xueying Mao, Xin Guo, Guo-min Wang, Zan Sun, G. Giles, M. Southey, R. MacInnis, L. FitzGerald, A. Kibel, B. Drake, A. Vega, A. Gómez-Caamaño, R. Szulkin, M. Eklund, M. Kogevinas, J. Llorca, G. Castaño‐Vinyals, K. Penney, M. Stampfer, Jong Park, T. Sellers, Hui-Yi Lin, J. Stanford, C. Cybulski, D. Wokołorczyk, J. Lubiński, E. Ostrander, M. Geybels, B. Nordestgaard, S. Nielsen, Maren Weischer, R. Bisbjerg, M. Røder, P. Iversen, H. Brenner, Katarina Ćuk, B. Holleczek, C. Maier, Manuel Luedeke, T. Schnoeller, Jeri Kim, C. Logothetis, E. John, M. Teixeira, P. Paulo, Marta Cardoso, S. Neuhausen, L. Steele, Y. Ding, K. Ruyck, G. Meerleer, P. Ost, A. Razack, Jasmine Lim, S. Teo, D. Lin, Lisa Newcomb, D. Lessel, M. Gamulin, T. Kuliš, R. Kaneva, N. Usmani, S. Singhal, C. Slavov, V. Mitev, M. Parliament, F. Claessens, S. Joniau, T. Broeck, Samantha Larkin, P. Townsend, Claire Aukim-Hastie, M. Gago-Domínguez, J. Castelao, M. Martínez, M. Roobol, G. Jenster, R. Schaik, F. Menegaux, Thérèse Truong, Y. Koudou, Jianfeng Xu, K. Khaw, L. Cannon-Albright, H. Pandha, A. Michael, S. Thibodeau, S. McDonnell, D. Schaid, S. Lindstrom, Constance Turman, Jing Ma, D. Hunter, E. Riboli, A. Siddiq, F. Canzian, L. Kolonel, L. Marchand, R. Hoover, M. Machiela, Z. Cui, P. Kraft, C. Amos, D. Conti, D. Easton, F. Wiklund, S. Chanock, B. Henderson, Z. Kote-Jarai, C. Haiman, R. Eeles (2018)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility lociNature Genetics, 50
N. Mottet, R. Bergh, E. Briers, T. Broeck, M. Cumberbatch, M. Santis, S. Fanti, N. Fossati, G. Gandaglia, S. Gillessen, N. Grivas, J. Grummet, A. Henry, T. Kwast, T. Lam, M. Lardas, M. Liew, M. Mason, L. Moris, D. Oprea-Lager, H. Poel, O. Rouvière, I. Schoots, D. Tilki, T. Wiegel, P. Willemse, P. Cornford (2020)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.European urology
M. Preston, Julie Batista, K. Wilson, S. Carlsson, T. Gerke, D. Sjoberg, D. Dahl, H. Sesso, A. Feldman, P. Gann, A. Kibel, A. Vickers, L. Mucci (2016)
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 23
W. Catalona, Deborah Smith, T. Ratliff, K. Dodds, D. Coplen, J. Yuan, J. Petros, G. Andriole (1991)
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.The New England journal of medicine, 324 17
X. Filella, M. Albaladejo, J. Allué, M. Castaño, D. Morell-Garcia, Maria Ruiz, M. Santamaria, M. Torrejón, N. Giménez (2019)
Prostate cancer screening: guidelines review and laboratory issuesClinical Chemistry and Laboratory Medicine (CCLM), 57
D. Dalela, M. Sun, M. Diaz, P. Karabon, T. Seisen, Q. Trinh, M. Menon, F. Abdollah (2017)
Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses.European urology focus, 5 1
M. Bandini, E. Mazzone, F. Preisser, S. Nazzani, E. Zaffuto, M. Marchioni, Z. Tian, R. Pompe, D. Tilki, M. Graefen, S. Shariat, F. Montorsi, F. Saad, A. Briganti, P. Karakiewicz (2018)
Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.European urology oncology, 1 4
A. Vickers, D. Sjoberg, D. Ulmert, E. Vertosick, M. Roobol, I. Thompson, E. Heijnsdijk, H. Koning, Coral Atoria-Swartz, P. Scardino, H. Lilja (2014)
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigenBMC Medicine, 12
J. Hugosson, M. Roobol, M. Månsson, T. Tammela, M. Zappa, V. Nelen, M. Kwiatkowski, M. Luján, S. Carlsson, K. Talala, H. Lilja, L. Denis, F. Recker, Á. Páez, D. Puliti, A. Villers, X. Rébillard, T. Kilpeläinen, U. Stenman, R. Godtman, K. Kollberg, S. Moss, P. Kujala, K. Taari, A. Huber, T. Kwast, E. Heijnsdijk, C. Bangma, H. Koning, F. Schröder, A. Auvinen (2019)
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.European urology, 76 1
V. Kasivisvanathan, A. Rannikko, M. Borghi, V. Panebianco, L. Mynderse, M. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R. Hindley, M. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G. Villeirs, J. Virdi, S. Boxler, G. Robert, Paras Singh, W. Venderink, B. Hadaschik, A. Ruffion, Jim Hu, D. Margolis, S. Crouzet, L. Klotz, S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, C. Moore (2018)
MRI‐Targeted or Standard Biopsy for Prostate‐Cancer DiagnosisThe New England Journal of Medicine, 378
(2020)
Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Jama
(2010)
American Cancer Society Guideline for the Early Detection of Prostate Cancer Update
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
T. Wang, T. Kawaguchi (1986)
Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer.Annals of clinical and laboratory science, 16 6
E. Johansson, G. Steineck, L. Holmberg, J. Johansson, T. Nyberg, M. Ruutu, A. Bill-Axelson (2011)
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.The Lancet. Oncology, 12 9
V. Moyer (2012)
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 157
Hodgkin Lymphoma (2014)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
James Kearns, D. Lin (2018)
Improving the Specificity of PSA Screening with Serum and Urine MarkersCurrent Urology Reports, 19
L. Bellardita, S. Villa, R. Valdagni (2014)
Living with untreated prostate cancer: predictors of quality of lifeCurrent Opinion in Urology, 24
S. Carlsson, M. Assel, D. Sjoberg, D. Ulmert, J. Hugosson, H. Lilja, A. Vickers (2014)
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort studyThe BMJ, 348
A. Tsodikov, R. Gulati, E. Heijnsdijk, P. Pinsky, S. Moss, S. Qiu, T. Carvalho, J. Hugosson, C. Berg, A. Auvinen, G. Andriole, M. Roobol, E. Crawford, V. Nelen, M. Kwiatkowski, M. Zappa, Marcos Lujn, A. Villers, E. Feuer, H. Koning, A. Mariotto, Ruth Etzioni (2017)
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsAnnals of Internal Medicine, 167
Andrew Vickers, D. Ulmert, Daniel Sjoberg, Caroline Bennette, T. Björk, A. Gerdtsson, J. Manjer, P. Nilsson, A. Dahlin, A. Bjartell, P. Scardino, H. Lilja (2013)
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control studyBMJ : British Medical Journal, 346
C. Bravi, A. Tin, E. Vertosick, E. Mazzone, A. Martini, P. Dell’Oglio, A. Stabile, G. Gandaglia, N. Fossati, N. Suardi, A. Gallina, A. Briganti, F. Montorsi, A. Vickers (2019)
The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study.Journal of Urology
Katherine Fleshner, S. Carlsson, M. Roobol (2017)
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USANature Reviews Urology, 14
S. Cantor, R. Volk, A. Cass, J. Gilani, S. Spann (2002)
Psychological benefits of prostate cancer screening: the role of reassuranceHealth Expectations, 5
B. Löppenberg, D. Friedlander, A. Krasnova, Andrew Tam, J. Leow, P. Nguyen, H. Barry, S. Lipsitz, M. Menon, F. Abdollah, J. Sammon, M. Sun, T. Choueiri, A. Kibel, Q. Trinh (2018)
Variation in the use of active surveillance for low‐risk prostate cancerCancer, 124
This JAMA Patient Page discusses the US Preventive Services Task Force’s recommendations on screening for prostate cancer in asymptomatic men.
JAMA – American Medical Association
Published: May 8, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.